<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Sept. 10, 2019 (HealthDay News) — The expected number of patients with hemophilia worldwide is 1,125,000 male patients, with 418,000 severe cases, according to research published online Sept. 10 in the Annals of Internal Medicine<\/i>.<\/p>\n
Alfonso Iorio, M.D., Ph.D., from McMaster University in Hamilton, Ontario, Canada, and colleagues estimated the prevalence and prevalence at birth of hemophilia in a random effects meta-analysis of registry data from Australia, Canada, France, Italy, New Zealand, and the United Kingdom.<\/p>\n
The researchers found that per 100,000 men\/boys, the prevalence was 17.1 and 6.0 cases for all severities of hemophilia A and for severe hemophilia A, respectively, and 3.8 and 1.1 cases for all severities of hemophilia B and severe hemophilia B, respectively. Per 100,000 men\/boys, the prevalence at birth was 24.6 and 9.5 cases for all severities of hemophilia A and for severe hemophilia A, respectively, and 5.0 and 1.5 cases for all severities of hemophilia B and severe hemophilia B, respectively. For high-income countries, the life expectancy disadvantage was 30 and 37 percent for hemophilia A and severe hemophilia A, respectively, and 24 and 27 percent for hemophilia B and severe hemophilia B, respectively. Worldwide, the expected number of patients with hemophilia is 1,125,000; 418,000 of these should have severe hemophilia.<\/p>\n
“Our analytic approach and results constitute a solid base for the future assessment of burden of disease in specific settings and worldwide,” the authors write.<\/p>\n
Several authors disclosed financial ties to the pharmaceutical industry.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n